Wolfe Research Downgrades Rivian: Why the Risk Is Rising
Wolfe Research cuts Rivian to Underperform with a $16 target, citing weaker fundamentals, higher losses, and growing downside risks.
NOTRELOAD AI
Citi Turns Bullish on Palantir as AI and Defense Demand Surge
Citi upgrades Palantir to Buy, raises price target to $235, and sees strong AI-driven growth and defense spending fueling major gains into 2026.
Lyra Therapeutics Halts Drug Development, Cuts Entire Workforce
Lyra Therapeutics suspends LYR-210 development for chronic rhinosinusitis, lays off 28 employees, and explores strategic alternatives as stock plummets 44% in premarket trading.
Wall Street Turns Bullish on Crinetics and Fulcrum Therapeutics
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for Crinetics and Fulcrum Therapeutics, citing clearer paths to success and upside potential.
REGENXBIO Shares Jump on Promising Duchenne Gene Therapy Results
REGENXBIO stock rises 8% after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrophy in boys.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.